366 related articles for article (PubMed ID: 30391079)
21. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients.
Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Mazzone E; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2018 Aug; 1(3):215-222. PubMed ID: 31102624
[TBL] [Abstract][Full Text] [Related]
22. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier.
Tosoian JJ; Birer SR; Jeffrey Karnes R; Zhang J; Davicioni E; Klein EE; Freedland SJ; Weinmann S; Trock BJ; Dess RT; Zhao SG; Jackson WC; Yamoah K; Dal Pra A; Mahal BA; Morgan TM; Mehra R; Kaffenberger S; Salami SS; Kane C; Pollack A; Den RB; Berlin A; Schaeffer EM; Nguyen PL; Feng FY; Spratt DE
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):646-653. PubMed ID: 32231245
[TBL] [Abstract][Full Text] [Related]
23. Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy.
Shangguan X; Qian H; Jiang Z; Xin Z; Pan J; Dong B; Xue W
J Cancer Res Clin Oncol; 2020 Mar; 146(3):687-694. PubMed ID: 31745702
[TBL] [Abstract][Full Text] [Related]
24. Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.
Cuzick JM; Stone S; Lenz L; Flake DD; Rajamani S; Moller H; Berney DM; Cohen T; Scardino PT
Cancer Rep (Hoboken); 2022 Aug; 5(8):e1535. PubMed ID: 34423592
[TBL] [Abstract][Full Text] [Related]
25. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
Cooperberg MR; Broering JM; Carroll PR
J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351
[TBL] [Abstract][Full Text] [Related]
26. Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Alves de Inda M; van Strijp D; den Biezen-Timmermans E; van Brussel A; Wrobel J; van Zon H; Vos P; Baillie GS; Tennstedt P; Schlomm T; Houslay MD; Bangma C; Hoffmann R
Eur Urol Focus; 2018 Apr; 4(3):376-384. PubMed ID: 28753810
[TBL] [Abstract][Full Text] [Related]
27. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
28. Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.
Cooperberg MR; Cowan JE; Lindquist KJ; Kobayashi Y; Simko JP; Bengtsson H; Singh K; Ngo V; Avila A; Newcomb LF; Tretriakova M; Lin DW; Stone S; Carroll PR; Paris PL
Eur Urol; 2021 Jan; 79(1):141-149. PubMed ID: 33148472
[TBL] [Abstract][Full Text] [Related]
29. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
30. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men.
Timofeeva OA; Zhang X; Ressom HW; Varghese RS; Kallakury BV; Wang K; Ji Y; Cheema A; Jung M; Brown ML; Rhim JS; Dritschilo A
Int J Oncol; 2009 Oct; 35(4):751-60. PubMed ID: 19724911
[TBL] [Abstract][Full Text] [Related]
31. Validation of the Combined Clinical Cell-Cycle Risk Score to Prognosticate Early Prostate Cancer Metastasis From Biopsy Specimens and Comparison With Other Routinely Used Risk Classifiers.
Hutten RJ; Odei B; Johnson SB; Tward JD
JCO Precis Oncol; 2024 Feb; 8():e2300364. PubMed ID: 38330260
[TBL] [Abstract][Full Text] [Related]
32. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).
Schymura MJ; Kahn AR; German RR; Hsieh MC; Cress RD; Finch JL; Fulton JP; Shen T; Stuckart E
BMC Cancer; 2010 Apr; 10():152. PubMed ID: 20403178
[TBL] [Abstract][Full Text] [Related]
33. Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.
Walker SM; Knight LA; McCavigan AM; Logan GE; Berge V; Sherif A; Pandha H; Warren AY; Davidson C; Uprichard A; Blayney JK; Price B; Jellema GL; Steele CJ; Svindland A; McDade SS; Eden CG; Foster C; Mills IG; Neal DE; Mason MD; Kay EW; Waugh DJ; Harkin DP; Watson RW; Clarke NW; Kennedy RD
Eur Urol; 2017 Oct; 72(4):509-518. PubMed ID: 28408174
[TBL] [Abstract][Full Text] [Related]
34. A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men.
Murphy AB; Carbunaru S; Nettey OS; Gornbein C; Dixon MA; Macias V; Sharifi R; Kittles RA; Yang X; Kajdacsy-Balla A; Gann P
Urology; 2020 Aug; 142():166-173. PubMed ID: 32277993
[TBL] [Abstract][Full Text] [Related]
35. Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.
Jain S; Lyons CA; Walker SM; McQuaid S; Hynes SO; Mitchell DM; Pang B; Logan GE; McCavigan AM; O'Rourke D; McArt DG; McDade SS; Mills IG; Prise KM; Knight LA; Steele CJ; Medlow PW; Berge V; Katz B; Loblaw DA; Harkin DP; James JA; O'Sullivan JM; Kennedy RD; Waugh DJ
Ann Oncol; 2018 Jan; 29(1):215-222. PubMed ID: 29045551
[TBL] [Abstract][Full Text] [Related]
36. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate.
Cross CK; Shultz D; Malkowicz SB; Huang WC; Whittington R; Tomaszewski JE; Renshaw AA; Richie JP; D'Amico AV
J Clin Oncol; 2002 Jun; 20(12):2863-8. PubMed ID: 12065563
[TBL] [Abstract][Full Text] [Related]
37. Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2017; 17(6):1-75. PubMed ID: 28572867
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.
Kamoun A; Cancel-Tassin G; Fromont G; Elarouci N; Armenoult L; Ayadi M; Irani J; Leroy X; Villers A; Fournier G; Doucet L; Boyault S; Brureau L; Multigner L; Diedhiou A; Roupret M; Compérat E; Blanchet P; de Reyniès A; Cussenot O
Ann Oncol; 2018 Aug; 29(8):1814-1821. PubMed ID: 29945238
[TBL] [Abstract][Full Text] [Related]
39. Improving risk stratification in a community-based African American population using cell cycle progression score.
Rayford W; Greenberger M; Bradley RV
Transl Androl Urol; 2018 Sep; 7(Suppl 4):S384-S391. PubMed ID: 30363476
[TBL] [Abstract][Full Text] [Related]
40. Predictors of Gleason score upgrading in a large African-American population.
Vora A; Large T; Aronica J; Haynes S; Harbin A; Marchalik D; Nissim H; Lynch J; Bandi G; McGeagh K; Kowalczyk K; Ghasemian R; Venkatesan K; Verghese M; Hwang J
Int Urol Nephrol; 2013 Oct; 45(5):1257-62. PubMed ID: 23864415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
